Immunoglobulin fusion proteins, their production and use

US7253264B1 · kind B1 · utility

Assignees

• Sanofi-Arentideutschland GmbH · DE
• The General Hospital Corporation · US

Inventors

• Leander Lauffer · Gladenbach, DE
• Gerd Zettlmeissl · Lahntal, DE
• Patricia Oquendo · Marburg, DE
• Brian Seed · Boston, US

Key dates

• Filing date: Aug 22, 1994
• Grant date: Aug 7, 2007
• Expiry date: Aug 22, 2014

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to genetically engineered soluble fusion proteins composed of human proteins not belonging to the immunoglobulin family, or of parts thereof, and of various portions of the constant region of immunoglobulin molecules. The functional properties of the two fusion partners are surprisingly retained in the fusion protein.